Method for producing H7 subtype avian influenza virus inactivated vaccine by using low-immunity chick embryo

An avian influenza virus and inactivated vaccine technology, which is applied in the directions of microorganism-based methods, veterinary vaccines, biochemical equipment and methods, etc. Effect

Active Publication Date: 2020-12-29
广东永顺生物制药股份有限公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The present invention aims at the problem that the H7 subtype avian influenza virus inactivated vaccine in the prior art mainly relies on SPF chicken embryos or non-immune chicken embryos, and its production cost is high, and aims to provide a method for producing H7 subtype avian influenza using low-immune chicken embryos Method of virus inactivated vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for producing H7 subtype avian influenza virus inactivated vaccine by using low-immunity chick embryo
  • Method for producing H7 subtype avian influenza virus inactivated vaccine by using low-immunity chick embryo
  • Method for producing H7 subtype avian influenza virus inactivated vaccine by using low-immunity chick embryo

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1: the impact of seed virus dilution on low immunity chicken embryo culture H7 subtype avian influenza virus

[0028] The company found in research and development that aspartic acid, ZnCl 2 and epidermal growth factor have a certain influence on the growth of chicken embryos and the proliferation of viruses in chicken embryos. In order to obtain the most suitable dilution of seed virus and improve the effect of virus proliferation in low-free chicken embryos, the company optimized aspartic acid acid, ZnCl 2 and the amount of addition of epidermal growth factor, through early research and development, it is found that the most suitable concentration of aspartic acid is 1.5 mg / mL, therefore, in the present invention, further ZnCl 2 and epidermal growth factor and its dosage have been further optimized test, the specific test design is as follows:

[0029] The culture method of H7 subtype avian influenza virus, after the H7 subtype avian influenza virus seed ...

Embodiment 2

[0039] Embodiment 2: Utilize the method for the production of H7 subtype avian influenza virus inactivated vaccine by low immunity chicken embryo

[0040] Step 1, get the H7 subtype avian influenza virus H7-Re2 strain virus seed and do 10 times serial dilution with the seed virus diluent, get 10 -4 For the diluted virus solution, inoculate 10-11-day-old low-immune chicken embryos in the allantoic cavity, 0.1ml per embryo, and continue to incubate at 37°C after inoculation, without turning the eggs;

[0041] Step 2: After inoculation of the chicken embryos, put eggs twice a day, discard the chicken embryos that died before 24 hours, take out the dead chicken embryos at any time after 24 hours, and take out all the live embryos at 72 hours, and the air chamber is upright , placed in a refrigerator at 2-8°C for 12 hours.

[0042] Step 3: Take out the chicken embryos that have been cooled for 12 hours, and after the surface is sterilized, push them into the harvesting operation r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

By improving the seed virus diluent, adding aspartic acid, ZnCl2 and epidermal growth factors in a specific proportion on the basis of a phosphate buffer, so that the H7 subtype avian influenza virusin the low-immunity chick embryo can be efficiently proliferated. The level of virus proliferation and the immune effect of the prepared vaccine are basically close to those of SPF chick embryos and non-immune chick embryos, however, the production cost is effectively reduced, the production threshold is lowered, which has a positive significance in production of H7 subtype avian influenza vaccines.

Description

Technical field: [0001] The invention belongs to the field of biotechnology, and in particular relates to a method for producing H7 subtype avian influenza virus inactivated vaccine by using low-immune chicken embryos. Background technique: [0002] Avian Influenza (Avian Influenza) is a severe infectious disease of poultry caused by the Orthomyxoviridae Influenza A virus, which is classified as a Class I infectious disease by the OIE. Death, can also infect mammals and humans. Since 2003, highly pathogenic avian influenza has been widely prevalent in our country and many countries in the world, causing huge economic losses to the poultry industry, and at the same time, threatening human health. Vaccination is currently the most important means of prevention for the prevention and control of bird flu. [0003] In the production of avian influenza vaccines, the chicken embryo method is mainly used at present, and SPF chicken embryos or non-immune chicken embryos are usually...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/02A61K39/145A61P31/16C12R1/93
CPCA61K39/12A61K2039/5252A61K2039/552A61P31/16C12N7/00C12N2760/16134C12N2760/16151
Inventor 杨傲冰陈坚史大庆穆光慧胡美容王千菊郑铁锁侯高伟孙彩宜陈金仙
Owner 广东永顺生物制药股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap